Anti-CD19 CAR T cell therapy for refractory SLE-ITP - PubMed
7 hours ago
- #SLE-ITP
- #CAR-T
- #immunotherapy
- Anti-CD19 CAR T cell therapy was tested in a single-arm, dose-escalation trial for refractory SLE-ITP.
- Six patients received the therapy after lymphodepleting chemotherapy, with safety as the primary outcome.
- All patients achieved clinical response (CR or PR), with three attaining complete remission (CR).
- Treatment-related adverse events were limited to grade 1 cytokine release syndrome in two patients, with no ICANS observed.
- Exploratory single-cell multi-omics revealed dysregulated pathways in bone marrow plasma cells and B cells in PR patients.
- The study supports CD19 CAR T cell therapy as a promising and safe treatment for refractory SLE-ITP, but large-scale trials are needed for verification.